HSIC vs MRK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
HSIC exhibits strong fundamental health with a Piotroski F-Score of 7/9, indicating robust operational efficiency and financial stability. While the current price of $75.34 is well above the defensive Graham Number ($45.41), it trades at a discount to its growth-based intrinsic value of $89.60 and the analyst target of $89.23. The company shows positive YoY revenue and earnings growth, though thin profit margins and bearish insider sentiment provide a cautionary counterweight. Overall, the valuation appears attractive on a forward P/E basis (12.82) relative to its historical stability.
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
HSIC vs MRK: Head-to-Head Comparison
This page compares Henry Schein, Inc. (HSIC) and Merck & Co., Inc. (MRK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.